GlassScriptPhysician profile
Erin Bergin
NPI 1376079137
$8,038.37
in general payments reported to CMS, 2019-2025
38 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,481 · 2022: $1,509 · 2023: $1,483 · 2024: $1,810 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.74 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,319.29 | 2021-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $975.66 | 2021-2025 | |
| Pfizer INC. | $807.14 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $763.99 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $707.53 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $590.45 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $376.82 | 2022-2025 | |
| Glaxosmithkline, LLC. | $262.87 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $207.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $197.99 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $187.62 | 2021-2022 | |
| Abbott Laboratories | $171.98 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Currax Pharmaceuticals LLC | $159.56 | 2021-2024 | Contrave, Nexletol, Onzetra Xsail |
| Shield Therapeutics INC | $118.01 | 2022-2025 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.14 | 2024-2025 | Caplyta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.